Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children's Cancer Group.

Abstract:

:Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21 ;q23). We studied the cytogenetics of the leukemia cells of 56 infants on CCG-1883, a single-arm clinical treatment protocol for infant ALL. Twenty-one patients had t(4;11)(q21;q23), seven had other rearrangements with breakpoints in 11q23 (other 11q23), 16 had normal chromosomes, two had t(1;19)(q32;p13), one had >50 chromosomes, and nine had non-recurring structural abnormalities. To determine whether there is a difference in outcome for infants with t(4;11), other 11q23 and the remaining patients, we compared event-free survival (EFS) and other clinical and laboratory features of the above infants. Infants without t(4;11) and those with other 11q23 rearrangements had significantly better EFS than those with t(4;11) (P= 0.007 and P= 0.02, respectively). t(4;11) correlated with age less than 6 months and with CD10 negativity, both of which also were poor prognostic indicators. After adjustment for age, there was still a significant difference in EFS between patients with t(4;11) and those with other 1lq23 rearrangements (P=0.02), and between patients with t(4;11) and those without t(4;11) (P=0.04). Among CD10 negative patients, t(4;11) was associated with a worse EFS (P=0.01). Multivariate analysis showed that after adjusting for a variety of clinical and laboratory features, t(4;11) was the most important prognostic factor for poor outcome, and patients with other 11q23 rearrangements had as good an outcome as the remaining patients without t(4;11).

journal_name

Leukemia

journal_title

Leukemia

authors

Heerema NA,Sather HN,Ge J,Arthur DC,Hilden JM,Trigg ME,Reaman GH

doi

10.1038/sj.leu.2401413

subject

Has Abstract

pub_date

1999-05-01 00:00:00

pages

679-86

issue

5

eissn

0887-6924

issn

1476-5551

journal_volume

13

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

    abstract::Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.50

    authors: Wild J,Schmiedel BJ,Maurer A,Raab S,Prokop L,Stevanović S,Dörfel D,Schneider P,Salih HR

    更新日期:2015-08-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.197

    authors: Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期:2013-12-01 00:00:00

  • De novo gene mutations in normal human memory B cells.

    abstract::In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0289-4

    authors: Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

    更新日期:2019-05-01 00:00:00

  • Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

    abstract::Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-020-0758-4

    authors: Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

    更新日期:2020-09-01 00:00:00

  • Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.

    abstract::Four randomized prospective studies on interferon alpha (IFN) in CML report varying degrees of prolongation of the chronic phase of CML and of survival as compared to conventional therapies. There is agreement that IFN prolongs survival as compared to standard busulfan. There is disagreement, however, as to which degr...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Hehlmann R,Willer A,Heimpel H,Hasford J,Kolb HJ,Pralle H,Hossfeld DK,Queisser W,Löffler H,Hochhaus A,Tobler A,Lengfelder E,Berger U,Leib-Mösch C

    更新日期:1997-04-01 00:00:00

  • Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

    abstract::Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.46

    authors: Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

    更新日期:2017-10-01 00:00:00

  • Monocytic involvement by monosomy 7 preceded acute myelomonocytic leukemia in a patient with myelodysplastic syndrome.

    abstract::Novel techniques were used to detect which cell lineages were affected by monosomy 7 in a patient who had myelodysplastic syndrome and later developed acute leukemia. The patient had had paroxysmal nocturnal hemoglobinuria for 20 years before developing refractory anemia with excess of blasts. Cytogenetic analysis at ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kere J,Knuutila S,Ruutu T,Leskinen R,de la Chapelle A

    更新日期:1988-02-01 00:00:00

  • YAC clone H10 discriminates between 3q26.2 and 3q27 chromosome rearrangements in hematological disorders.

    abstract::To discriminate with molecular-cytogenetic resolution between 3q26.2 breakpoint, associated to various myeloproliferative disorders, and 3q27 breakpoint, recurrent in several types of non-Hodgkin lymphoma, we tested the feasibility of using a yeast artificial chromosome, YAC clone H10, mapped on 3q26.3. Fluorescent in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Temperani P,Gandini G,Volinia S,Giacobbi F,Vaccari P,Waterfield MD,Emilia G

    更新日期:1996-02-01 00:00:00

  • Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.

    abstract::Blockade of tumor necrosis factor (TNF)alpha by a soluble TNF receptor fusion protein (etanercept; Enbrel) improved in vitro hemopoiesis from the marrow of patients with myelodysplastic syndrome (MDS). Therefore, we enrolled 14 MDS patients (4 RA, 2 RARS, 6 RAEB, 2 CMML), 44-80 (median 60) years old, in a pilot trial....

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402356

    authors: Deeg HJ,Gotlib J,Beckham C,Dugan K,Holmberg L,Schubert M,Appelbaum F,Greenberg P

    更新日期:2002-02-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Molecular cloning of a 5' segment of the genomic phl gene defines a new breakpoint cluster region (bcr2) in Philadelphia-positive acute leukemias.

    abstract::Molecular rearrangements of Ph1 chromosome, the hallmark of CML, are clustered in a 5.8-kb DNA segment, the so-called breakpoint cluster region (bcr) of the phl gene that is localized to chromosome 22q11. In Ph1-positive (Ph1+) ALLs, the rearrangements have been shown to involve either the 5.8-kb bcr (called bcr+) or ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Chen SJ,Chen Z,Grausz JD,Hillion J,d'Auriol L,Flandrin G,Larsen CJ,Berger R

    更新日期:1988-10-01 00:00:00

  • Leptin receptor, a surface marker for a subset of highly engrafting long-term functional hematopoietic stem cells.

    abstract::The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01079-z

    authors: Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

    更新日期:2020-11-07 00:00:00

  • Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

    abstract::The current study was undertaken to search for differences in the biology of cytogenetic subgroups in patients with de novo acute myeloid leukemia (AML). In addition, factors influencing the metabolism of cytosine arabinoside (araC) as the key agent of antileukemic activity were assessed. Bone marrow aspirates from 91...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402029

    authors: Jahns-Streubel G,Braess J,Schoch C,Fonatsch C,Haase D,Binder C,Wörmann B,Büchner T,Hiddemann W

    更新日期:2001-03-01 00:00:00

  • Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

    abstract::The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.257

    authors: Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

    更新日期:2018-02-01 00:00:00

  • Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.

    abstract::The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in long-term complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or rel...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401128

    authors: Marcucci G,Livak KJ,Bi W,Strout MP,Bloomfield CD,Caligiuri MA

    更新日期:1998-09-01 00:00:00

  • Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis.

    abstract::We performed cytogenetic and molecular analysis of the BCR-ABL rearrangement by polymerase chain reaction (PCR) in 39 consecutive cases of adult acute lymphoblastic leukemia (ALL). Eleven patients had a Philadelphia (Ph) chromosome. Thirteen patients had a BCR-ABL rearrangement, involving minor breakpoint cluster regi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Preudhomme C,Fenaux P,Lal JL,Lepelley P,Sartiaux C,Collyn-d'Hooghe M,Zandecki M,Cosson A,Jouet JP,Kerckaert JP

    更新日期:1993-07-01 00:00:00

  • Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia.

    abstract::Twenty new cases of acute lymphoblastic leukemia (ALL) with the dicentric chromosome dic(9;20)(p1113;q11) are presented. This chromosomal abnormality is difficult to identify from G-banding alone. It masquerades as monosomy 20 and is only accurately identified by fluorescence in situ hybridization (FISH). Monosomy 20 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401654

    authors: Clark R,Byatt SA,Bennett CF,Brama M,Martineau M,Moorman AV,Roberts K,Secker-Walker LM,Richards S,Eden OB,Goldstone AH,Harrison CJ

    更新日期:2000-02-01 00:00:00

  • Childhood monosomy 7 syndrome: clinical and in vitro studies.

    abstract::The clinical and cell growth characteristics of 11 children with monosomy 7 presenting as preleukemia (eight cases) or acute nonlymphoblastic leukemia (three cases) were studied. Anemia was common to all patients, with nine showing leukocytosis, seven thrombocytopenia, and one thrombocytosis. There was a striking pred...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Weiss K,Stass S,Williams D,Kalwinsky D,Dahl GV,Wang W,Johnson FL,Murphy SB,Dow LW

    更新日期:1987-02-01 00:00:00

  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract::The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0986-7

    authors: Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期:2020-09-01 00:00:00

  • Efficient gene transfer in CLL by mRNA electroporation.

    abstract::Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405007

    authors: Van Bockstaele F,Pede V,Naessens E,Van Coppernolle S,Van Tendeloo V,Verhasselt B,Philippé J

    更新日期:2008-02-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract::The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期:1992-01-01 00:00:00

  • The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

    abstract::The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously described to impair cellular proliferation. The current study reveals that RPL10 R98S cells accumulate reactive oxygen species which promotes mitochondrial dysfunction a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0176-z

    authors: Kampen KR,Sulima SO,Verbelen B,Girardi T,Vereecke S,Rinaldi G,Verbeeck J,Op de Beeck J,Uyttebroeck A,Meijerink JPP,Moorman AV,Harrison CJ,Spincemaille P,Cools J,Cassiman D,Fendt SM,Vermeersch P,De Keersmaecker K

    更新日期:2019-02-01 00:00:00

  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

    abstract::Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failur...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-019-0512-y

    authors: Branford S,Kim DDH,Apperley JF,Eide CA,Mustjoki S,Ong ST,Nteliopoulos G,Ernst T,Chuah C,Gambacorti-Passerini C,Mauro MJ,Druker BJ,Kim DW,Mahon FX,Cortes J,Radich JP,Hochhaus A,Hughes TP,International CML Foundation Ge

    更新日期:2019-08-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0334-3

    authors: Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期:2019-06-01 00:00:00

  • HTLV-I Tax trans-activation and cell growth signaling.

    abstract::We have cloned two genes for cell surface molecules, capable of delivering the intracellular signals, which are modulated for their expression by Tax. One is the gamma chain of the interleukin-2 (IL-2) receptor which is suggested to be critical for IL-2-dependent growth of human T-cell leukemia virus type I (HTLV-I) i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Nakamura M,Takasawa N,Ohbo K,Higashimura N,Ohtani K,Tanaka Y,Sugamura K

    更新日期:1997-04-01 00:00:00

  • Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and l

    abstract::Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Morrison FS,Kopecky KJ,Head DR,Athens JW,Balcerzak SP,Gumbart C,Dabich L,Costanzi JJ,Coltman CA,Saiki JH

    更新日期:1992-07-01 00:00:00

  • Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dubois C,Schlageter MH,de Gentile A,Balitrand N,Toubert ME,Krawice I,Fenaux P,Castaigne S,Najean Y,Degos L

    更新日期:1994-10-01 00:00:00

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    abstract::Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0734-z

    authors: Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

    更新日期:2020-04-01 00:00:00

  • Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

    abstract::Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400678

    authors: Rockman SP

    更新日期:1997-06-01 00:00:00

  • Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.

    abstract::Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparabl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.267

    authors: Creutzig U,Zimmermann M,Bourquin JP,Dworzak MN,Kremens B,Lehrnbecher T,von Neuhoff C,Sander A,von Stackelberg A,Schmid I,Starý J,Steinbach D,Vormoor J,Reinhardt D

    更新日期:2012-04-01 00:00:00